Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

- "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" -

Toronto Stock Exchange Symbol: MS

EDMONTON, May 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Richard Brown, Vice President, Commercial Development, BioMS Medical and Mr. Jack Tupman, Senior Director, Corporate Business Development, Eli Lilly and Company, will take part in a Technology Transfer/Licensing session at the BIO International Convention 2009 in Atlanta, Georgia entitled "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration."

Also participating in the panel session will be Mr. Nitin Kaushal, Director, Healthcare Investment Banking, Desjardins Securities and Mr. Jeremy Webster, Senior VP & Director Deloitte & Touche, LLP. The moderator for the session will be Ms. Cheryl Reicin, Partner, Torys LLP.

    WHEN:     Thursday May 21st at 8:00am (Eastern Time)

    WHERE:    Room B316, Georgia World Congress Center, Atlanta, Georgia

    BioMS Medical will also provide a corporate presentation at the Business
Forum at 9:40am (Eastern Time) on Wednesday May 20th.

    About BIO International Convention
    ----------------------------------
    The BIO International Convention, hosted by the Biotechnology Industry
Organization, is the largest global event for the biotechnology industry and
attracts the biggest names in biotech, offers key networking and partnering
opportunities, and provides insights and inspiration on major trends affecting
the industry. For more information visithttp://convention.bio.org/.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OH (PRWEB) , ... August 16, 2017 , ... ... a beneficial microbe delivery system, announced it has secured $2M in funding from ... Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar ...
(Date:8/16/2017)... and OXFORD, England , Aug. 16, 2017 ... for biotech executive search and leadership development, and Virdis Group, ... have created an exclusive alliance that enables clients to leverage ... "For our clients here in the ... access to a diverse population of leadership talent throughout the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , ... development, announces the launch of the new NHS Agile biosensor chip . ... data for a wide range of molecules, including small and large molecules, peptides, ...
(Date:8/15/2017)... ... 2017 , ... Kenall, a leader in sealed solid-state lighting, ... sealed and perform efficiently for years. The downlights are ideal for a variety ... such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical processing ...
Breaking Biology Technology:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):